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lhe American College of Cardiology held its 59th
nnual Scientific Session in conjunction with the
nnovation in Intervention Summit in Atlanta,
eorgia, from March 14 to March 16, 2010,
resenting several breaking trials in the field of
nterventional Cardiology that are summarized
erein.
The 59th Annual Scientific Session of the
merican College of Cardiology (ACC) was held
n conjunction with the Innovation in Intervention
i2) Summit in Atlanta, Georgia, from March 14
o March 16, 2010, revealing several breaking trials
n the field of Interventional Cardiology. A sum-
ary of the key breaking trials and registries in
nterventional Cardiology is presented herein.
IR
meta-analysis of the FRISC (Framingham and
ast Revascularization During Instability in Cor-
nary Artery Disease II) trial (1), ICTUS (Invasive
ersus Conservative Treatment in Unstable Coro-
ary Syndromes) trial (2), and RITA (Randomized
ntervention Trial of Unstable Angina 3) trial
3)—known as the FIR trial collaboration (4)—
as initiated due to ambiguity about the long-term
ndings of the individual studies comparing a more
ggressive routine-invasive strategy with a more
onservative selective-invasive strategy among pa-
ients with non–ST-segment elevation acute coro-
ary syndrome. The combination of the 3 trials
otaled 5,467 patients, of whom 2,721 were ran-
omized to the routine invasive strategy, and 2,746
ere randomized to the selective-invasive strategy
rom the *Division of Cardiovascular Medicine, Deborah Heart and
ung Center, Browns Mills, New Jersey; †Division of Cardiovascular
edicine, Gill Heart Institute, University of Kentucky, Lexington,S
entucky; and the ‡Columbia University Medical Center, New York,
ew York.ollowed-up over 5 years. The study revealed that
utcomes of nonfatal myocardial infarction (MI)
lone and combined end points of cardiovascular
eath/MI and all-cause mortality/MI were signif-
cantly lower in the routine-invasive group com-
ared with the selective-invasive cohort. The dif-
erences in MI began to diverge within the first 3
onths and remained separated at 5 years. More-
ver, patients in the highest-risk group seemed to
enefit most from the routine-invasive strategy.
VEREST II
he EVEREST (Endovascular Valve Edge-to-
dge Repair Study II) (5) compared the safety and
fficacy of a percutaneous version of mitral valve
epair with the traditional surgical repair in a
elected patient population. The trial enrolled 279
atients with significant mitral regurgitation that
ere randomized 2:1 to percutaneous edge-to-
dge repair with the MitraClip device (Abbott,
vanston, Illinois) or to surgical repair or replace-
ent at the surgeon’s discretion. Primary end
oints of the study were major adverse events at 30
ays and clinical success rate, defined as freedom
rom a combination of death, mitral valve surgery,
r re-operation for mitral valve dysfunction and an
mprovement of at least 2 grades of mitral regur-
itation at 12 months. Superior safety and nonin-
erior efficacy with the device compared with sur-
ery was demonstrated, with slightly more
oderate regurgitation in the device group. These
esults will be discussed further in relation to
ossible regulatory approval of the studied device.
ET STENT
he JETSTENT (Comparison of AngioJet Rheo-
ytic Thrombectomy before Direct Infarct Artery
tenting to Direct Stenting Alone in Patients with
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563cute Myocardial Infarction) trial (6) evaluated the use of
heolytic thrombectomy before direct stenting of the
nfarct-related artery in patients with acute MI. In contrast
o the TAPAS (Thrombus Aspiration during Percutaneous
oronary Intervention in Acute Myocardial Infarction
tudy) (7), which showed improved reperfusion and clinical
utcomes with the use of a mechanical aspiration catheter,
he AiMI (AngioJet Rheolytic Thrombectomy in Patients
ndergoing Primary Angioplasty for Acute Myocardial
nfarction) study (8) previously showed that rheolytic
hrombectomy with AngioJet (Medrad Interventional/
ossis, Minneapolis, Minnesota) did not significantly re-
uce infarct size. The JETSTENT study, however, only
ncluded patients with angiographically visible thrombus,
nd thrombectomy was performed with a single-pass ante-
rade approach moving in a proximal-to-distal direction in
n attempt to prevent embolization, and this was associated
ith better reperfusion defined by significantly greater
chievement of 50% ST-segment resolution at 30 min and
rends toward lower major adverse cardiac events at 30 days
nd 6 months. By contrast, no difference was documented in
nfarct size.
AIN-COMPARE 5-Year
he MAIN-COMPARE (Revascularization for Unpro-
ected Left Main Coronary Artery Stenosis: Comparison of
ercutaneous Coronary Angioplasty Versus Surgical Revas-
ularization) registry (9) compares percutaneous coronary
ntervention (PCI) versus coronary artery bypass grafting
CABG) for patients with unprotected left main coronary
rtery disease. Recent trials, including the SYNTAX (Syn-
rgy between PCI with Taxus and Cardiac Surgery) trial
10) and registry data including 3-year results from MAIN-
OMPARE (11) that have previously been published,
emonstrate similar composite end points of death, MI, and
troke.
The study involved 2,240 patients with unprotected left
ain coronary artery disease who received either PCI (n 
,102; bare-metal stents [BMS; n  318]; drug-eluting
tents [DES; n  784]) or CABG (n  1,138) and
ollowed-up for 5 years. After propensity-score matching to
educe the effect of treatment selection bias, the end points
f death and the combined risk of death, MI, or stroke were
imilar for PCI- and CABG-treated patients. However, the
ate of target vessel revascularization (TVR) was signifi-
antly higher in the PCI group. Stent type (BMS vs. DES)
id not significantly alter outcomes; TVR was 6% with DES
nd 11% with BMS.
ERSEUS
he PERSEUS (Prospective Evaluation of the Safety and
fficacy of the Taxus Element Paclitaxel-Eluting Coronary mtent System) trial (12) includes 2 parallel studies of the
ovel Taxus Element stent (Boston Scientific, Natick,
assachusetts), which is a paclitaxel-eluting stent over a
latinum-enriched metal alloy platform with a thinner
1-m strut for enhanced radio-opacity and improved
eliverability.
The PERSEUS Workhorse study involved 1,262 patients
ith lesions in coronary arteries ranging from 2.75 to 4.0
m in diameter and 28 mm in length, who were
andomized 3:1 to receive either the new Taxus Element or
he first generation Taxus Express paclitaxel-eluting stent.
arget lesion failure rates at 1 year, average percent diam-
ter stenosis at 9 months, and stent thrombosis (ST) at 1
ear were similar in both stent groups.
The PERSEUS Small Vessel study enrolled 224 patients
ith lesions in coronary arteries, ranging from 2.25 to 2.75
m in diameter and 20 mm in length, who received the
axus Element stent. Because no DES were Food and
rug Administration–approved for small vessels when the
ERSEUS trial began in 2007, the control group was a
atched historical Express BMS group from the TAXUS V
rial (13). At 9 months, the primary angiographic end point
f in-stent late loss and the rate of ST were significantly
ower in the TAXUS Element group (mean was 0.37 mm).
ORT OUT III
he SORT OUT III (Danish Organization for Random-
zed Trials with Clinical Outcome) study (14) is a prospec-
ive randomized comparison of 2 DES: the first-generation
irolimus-eluting stent (SES; Cypher, Cordis, Miami
akes, Florida) versus the second-generation zotarolimus-
luting stent (ZES; Endeavor, Medtronic, Minneapolis,
innesota). A total of 2,332 patients were randomized to
eceive either ZES (n  1,162) or SES (n  1,170) and
ere followed-up for 18 months. The primary end point,
hich was a composite of cardiovascular death, MI, and
VR, was significantly higher in the ZES group compared
ith SES. Secondary end points of all-cause mortality,
ardiovascular death, MI, ST, and TVR were also signifi-
antly higher in the ZES group. The results from this trial
iffer from the ENDEAVOR III trial (15), where there
ere no significant differences in major adverse cardiovas-
ular events between ZES and SES at up to 2 years. Some
f the proposed reasons for the discrepancy between the 2
rials note that SORT OUT III included all patients
ncluding complex lesions, such as bifurcations, ostial le-
ions, left main lesions, long lesions, chronic total occlu-
ions, acute coronary syndromes, and ST-segment elevation
I. At the same time, the SORT OUT III study used
dministrative databases for follow-up and did not include
arly (up to 5 days after procedure) events; thus, event rates
ight appear lower than reality.
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564SAR-TEST-2
he ISAR-TEST-2 (Intracoronary Stenting and Anti-
hrombotic Regimen-Test Efficacy of Dual Drug-Eluting
tents) trial (16) evaluated a novel dual drug-eluting stent
DDES) on a new polymer-free platform that elutes both
irolimus and probucol, an antihyperlipidemic drug. The trial
andomized 1,007 patients with de novo coronary lesions to
tenting with the first-generation SES (Cypher, Cordis, Mi-
mi Lakes, Florida), ZES (Endeavor, Medtronic, Minne-
polis, Minnesota), or the new DDES (Bavarian Research
oundation) and followed-up for 2 years. The new results
how that the anti-restenotic benefits of the new DDES
chieved at 1 year that were previously presented (17) were
aintained out to 2 years, although there is some level of
atch-up in binary restenosis and TLR in the SES group.
he ZES group had higher event rates than the other stents
t 1 year, but no increment was observed between 1 and 2
ears.
ummary
he 2010 ACC Annual Scientific Session presented new
ata on breaking clinical trials and established follow-up
ata on previously initiated trials in Interventional Cardiol-
gy that have been summarized. Complete coverage of the
CC/i2 Summit 2010 can be accessed at the ACC Car-
iosource website (18).
eprint requests and correspondence: Dr. Jon C. George,
irector of Clinical Research, Division of Cardiovascular Medi-
ine, Deborah Heart and Lung Center, 200 Trenton Road,
rowns Mills, New Jersey 08015. E-mail: jcgeorgemd@
otmail.com.
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